OBJECTIVES: The emergency department (ED) is a challenging setting to conduct pharmacogenomic studies and integrate that data into fast-paced and potentially life-saving treatment decisions. Therefore, our objective is to present the methods and feasibility of a pilot pharmacogenomic study set in the ED that measured pediatric bronchodilator response (BDR) during acute asthma exacerbations. METHODS: This is an exploratory pilot study that collected buccal swabs for DNA and measured BDR during ED encounters for pediatric asthma exacerbations. We evaluated the study's feasibility with a qualitative analysis of ED provider surveys and quantitatively by the proportion of eligible patients enrolled. RESULTS: We enrolled 59 out of 90 patients (65%) that were identified and considered eligible during a 5-month period (target enrollment 60 patients over 12 months). The median patient age was 7 years (interquartile range 4-9 years), 61% (N = 36) were male, and 92% (N = 54) were African American. Quality DNA collection was successful for all 59 patients. The ED provider survey response rate was 100%. Most ED providers reported that the study did not impact their workflow (98% of physicians, 88% of nurses, and 90% of respiratory therapists). ED providers did report difficulties with spirometry in the younger age group. CONCLUSIONS: Pharmacogenomic studies can be conducted in the ED setting, and enroll a younger patient population with a high proportion of minority participants. By disseminating this study's methods and feasibility analysis, we aim to increase interest in pharmacogenomic studies set in the ED and aimed toward future ED-based pharmacogenomic decision-making.
OBJECTIVES: The emergency department (ED) is a challenging setting to conduct pharmacogenomic studies and integrate that data into fast-paced and potentially life-saving treatment decisions. Therefore, our objective is to present the methods and feasibility of a pilot pharmacogenomic study set in the ED that measured pediatric bronchodilator response (BDR) during acute asthma exacerbations. METHODS: This is an exploratory pilot study that collected buccal swabs for DNA and measured BDR during ED encounters for pediatric asthma exacerbations. We evaluated the study's feasibility with a qualitative analysis of ED provider surveys and quantitatively by the proportion of eligible patients enrolled. RESULTS: We enrolled 59 out of 90 patients (65%) that were identified and considered eligible during a 5-month period (target enrollment 60 patients over 12 months). The median patient age was 7 years (interquartile range 4-9 years), 61% (N = 36) were male, and 92% (N = 54) were African American. Quality DNA collection was successful for all 59 patients. The ED provider survey response rate was 100%. Most ED providers reported that the study did not impact their workflow (98% of physicians, 88% of nurses, and 90% of respiratory therapists). ED providers did report difficulties with spirometry in the younger age group. CONCLUSIONS: Pharmacogenomic studies can be conducted in the ED setting, and enroll a younger patient population with a high proportion of minority participants. By disseminating this study's methods and feasibility analysis, we aim to increase interest in pharmacogenomic studies set in the ED and aimed toward future ED-based pharmacogenomic decision-making.
Authors: Mariam Naqvi; Shannon Thyne; Shweta Choudhry; Hui-ju Tsai; Daniel Navarro; Richard A Castro; Sylvette Nazario; Jose R Rodriguez-Santana; Jesus Casal; Alfonso Torres; Rocio Chapela; H Geoffrey Watson; Kelley Meade; Michael LeNoir; Pedro C Avila; William Rodriguez-Cintron; Esteban González Burchard Journal: J Asthma Date: 2007-10 Impact factor: 2.515
Authors: B Padhukasahasram; J J Yang; A M Levin; M Yang; E G Burchard; R Kumar; P-Y Kwok; M A Seibold; D E Lanfear; L K Williams Journal: Pharmacogenomics J Date: 2014-01-14 Impact factor: 3.550
Authors: Adaeze C Ayuk; Samuel N Uwaezuoke; Chizalu I Ndukwu; Ikenna K Ndu; Kenechukwu K Iloh; Chinyere V Okoli Journal: Clin Med Insights Pediatr Date: 2017-07-19
Authors: Christopher W Seymour; Hernando Gomez; Chung-Chou H Chang; Gilles Clermont; John A Kellum; Jason Kennedy; Sachin Yende; Derek C Angus Journal: Crit Care Date: 2017-10-18 Impact factor: 9.097
Authors: Larisa H Cavallari; Sara L Van Driest; Cynthia A Prows; Jeffrey R Bishop; Nita A Limdi; Victoria M Pratt; Laura B Ramsey; D Max Smith; Sony Tuteja; Benjamin Q Duong; J Kevin Hicks; James C Lee; Aniwaa Owusu Obeng; Amber L Beitelshees; Gillian C Bell; Kathryn Blake; Daniel J Crona; Lynn Dressler; Ryan A Gregg; Lindsay J Hines; Stuart A Scott; Richard C Shelton; Kristin Wiisanen Weitzel; Julie A Johnson; Josh F Peterson; Philip E Empey; Todd C Skaar Journal: Genet Med Date: 2019-03-21 Impact factor: 8.822
Authors: Florence T Bourgeois; Paul Avillach; Sek Won Kong; Michelle M Heinz; Tram A Tran; Ramkrishna Chakrabarty; Jonathan Bickel; Piotr Sliz; Erin M Borglund; Susan Kornetsky; Kenneth D Mandl Journal: J Pers Med Date: 2017-12-15
Authors: Melissa L Spear; Donglei Hu; Maria Pino-Yanes; Scott Huntsman; Celeste Eng; Albert M Levin; Victor E Ortega; Marquitta J White; Meghan E McGarry; Neeta Thakur; Joshua Galanter; Angel C Y Mak; Sam S Oh; Elizabeth Ampleford; Stephen P Peters; Adam Davis; Rajesh Kumar; Harold J Farber; Kelley Meade; Pedro C Avila; Denise Serebrisky; Michael A Lenoir; Emerita Brigino-Buenaventura; William Rodriguez Cintron; Shannon M Thyne; Jose R Rodriguez-Santana; Jean G Ford; Rocio Chapela; Andrés Moreno Estrada; Karla Sandoval; Max A Seibold; Cheryl A Winkler; Eugene R Bleecker; Deborah A Myers; L Keoki Williams; Ryan D Hernandez; Dara G Torgerson; Esteban G Burchard Journal: Pharmacogenomics J Date: 2018-09-12 Impact factor: 3.550